AR107735A1 - MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F - Google Patents

MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F

Info

Publication number
AR107735A1
AR107735A1 ARP160103878A ARP160103878A AR107735A1 AR 107735 A1 AR107735 A1 AR 107735A1 AR P160103878 A ARP160103878 A AR P160103878A AR P160103878 A ARP160103878 A AR P160103878A AR 107735 A1 AR107735 A1 AR 107735A1
Authority
AR
Argentina
Prior art keywords
tnf
human
interleucins
specificity
necrosis factor
Prior art date
Application number
ARP160103878A
Other languages
English (en)
Inventor
Daniel John Lightwood
Stevan Graham Shaw
Diane Marshall
David Paul Humphreys
Sam Philip Heywood
Emma Dave
Pallavi Bhatta
Ralph Adams
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of AR107735A1 publication Critical patent/AR107735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se refiere también a usos terapéuticos de las moléculas de anticuerpos en pacientes con artritis reumatoide y a métodos para producir dichas moléculas de anticuerpos. Reivindicación 1: Una molécula de anticuerpo multiespecífica que comprende un dominio de unión específico para el TNF-a humano y un dominio de unión específico para la IL-17A humana y la IL-17F humana, caracterizada porque la molécula de anticuerpo es capaz de neutralizar la actividad biológica del TNF-a humano, la IL-17A humana y la IL-17F humana.
ARP160103878A 2015-12-18 2016-12-16 MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F AR107735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522391.0A GB201522391D0 (en) 2015-12-18 2015-12-18 Antibody molecules

Publications (1)

Publication Number Publication Date
AR107735A1 true AR107735A1 (es) 2018-05-30

Family

ID=55311227

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103878A AR107735A1 (es) 2015-12-18 2016-12-16 MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F

Country Status (25)

Country Link
US (1) US20200277366A1 (es)
EP (1) EP3390445A1 (es)
JP (1) JP2019502380A (es)
KR (1) KR20180089514A (es)
CN (1) CN108473568A (es)
AR (1) AR107735A1 (es)
AU (1) AU2016369307A1 (es)
BR (1) BR112018011860A2 (es)
CA (1) CA3007493A1 (es)
CL (1) CL2018001660A1 (es)
CO (1) CO2018006667A2 (es)
EA (1) EA201891446A1 (es)
EC (1) ECSP18054047A (es)
GB (1) GB201522391D0 (es)
IL (1) IL259645A (es)
MA (2) MA44061A (es)
MX (1) MX2018007289A (es)
PH (1) PH12018501141A1 (es)
RU (1) RU2018126318A (es)
SG (1) SG11201804803WA (es)
TN (1) TN2018000200A1 (es)
TW (1) TW201726731A (es)
UY (1) UY37035A (es)
WO (1) WO2017102830A1 (es)
ZA (1) ZA201803681B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008075A2 (pt) 2015-10-27 2018-12-04 Ucb Biopharma Sprl métodos de tratamento usando anticorpos anti-il-17a/f
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
EP3917954A1 (en) 2019-01-31 2021-12-08 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022174813A1 (zh) * 2021-02-19 2022-08-25 信达生物制药(苏州)有限公司 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
WO2023035272A1 (zh) * 2021-09-13 2023-03-16 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
CA2721713C (en) * 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CA2853114A1 (en) * 2011-10-24 2013-05-02 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
EP3027649B1 (en) * 2013-08-01 2020-04-01 F.Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies

Also Published As

Publication number Publication date
IL259645A (en) 2018-07-31
US20200277366A1 (en) 2020-09-03
CO2018006667A2 (es) 2018-07-10
AU2016369307A1 (en) 2018-07-12
PH12018501141A1 (en) 2019-01-28
JP2019502380A (ja) 2019-01-31
EA201891446A1 (ru) 2018-11-30
GB201522391D0 (en) 2016-02-03
ECSP18054047A (es) 2018-07-31
RU2018126318A3 (es) 2020-05-20
UY37035A (es) 2017-07-31
MA44061A (fr) 2018-10-24
CN108473568A (zh) 2018-08-31
CL2018001660A1 (es) 2018-10-19
KR20180089514A (ko) 2018-08-08
MA42743A1 (fr) 2019-07-31
EP3390445A1 (en) 2018-10-24
SG11201804803WA (en) 2018-07-30
BR112018011860A2 (pt) 2018-12-04
CA3007493A1 (en) 2017-06-22
ZA201803681B (en) 2019-09-25
TN2018000200A1 (en) 2019-10-04
MX2018007289A (es) 2018-09-28
RU2018126318A (ru) 2020-01-20
TW201726731A (zh) 2017-08-01
WO2017102830A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
AR107735A1 (es) MOLÉCULAS DE ANTICUERPOS MULTIESPECÍFICAS QUE TIENEN ESPECIFICIDAD POR FACTOR DE NECROSIS TUMORAL a (TNF-a), INTERLEUCINAS: IL-17A E IL-17F
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
AR128047A2 (es) Moléculas de anticuerpos que se unen a il-17a e il-17f
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
GT201200125A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY35399A (es) Conjugados de fármacos con anticuerpos
DOP2010000368A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
PE20151410A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
AR107916A1 (es) ANTICUERPOS CONTRA EL FACTOR a DE LA NECROSIS TUMORAL (TNFa) Y FRAGMENTOS FUNCIONALES DE LOS MISMOS
CL2021002815A1 (es) Usos de anticuerpos anti-il-17a/f (divisional 2018-01135)
EA201891594A1 (ru) Антитела к il-17c
CO2018006555A2 (es) Moléculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa)
AR120818A1 (es) Anticuerpo multiespecífico con especificidad de unión por il-13 e il-17 humanas
EA201890983A1 (ru) Способы лечения с использованием анти-il-17a/f антител

Legal Events

Date Code Title Description
FB Suspension of granting procedure